Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Ivermectin --- Ivomec. --- Rindererkrankungen --- Rinderinfektion mit Räudemilben u. Rundwürmern. --- Räudemilben- u. Rundwürmerinfektion unter Ivomec®.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Swine --- Acarina --- Skin diseases --- Aetiology --- diagnosis --- Drug therapy --- Sarcoptes scabiei --- Ivermectin

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Introduction: Malaria affects 229 million people worldwide. It is a major public health problem, particularly in Africa where 95 % of the cases are found. The appearance of new resistances to current treatments is worrisome, and it is necessary to find alternatives in order to cure the affected population.

Material and Method: This work is divided in three phases: a cross-sectional study, a pre-experimental study, and a cost-effectiveness study. The cross-sectional study consists of a questionnaire sent to Gabon in order to collect the patients' feelings regarding the disease and the side effects of the treatment. The pre-experimental study assesses the effectiveness of the new strategy, i.e. treating mosquitoes rather than patients. The cost-effectiveness study determines if the strategy is more advantageous from an efficiency and financial point of view compared to the current strategies. 

Results: The cross-sectional study shows that patients suffer more from numerous side effects due to the treatment than from the disease itself. The most commonly used antimalarial drug is Coartem. 
The pre-experimental study shows the effectiveness of the new treatment. 95 % of the mosquitoes that came into contact with this formulation died after 24 hours. 
The cost-effectiveness study shows that the new strategy is more expensive than treatment strategies. However, after 20 years of implementation, the gap is narrowing. 

Conclusion: The implementation of the new strategy (i.e. treatment of the vector) is more expensive than the one of the current treatment strategies. However, this cost difference tends to decrease over time. In addition, it should be kept in mind that this strategy eliminates a quantity of mosquitoes each year, which would reduce the incidence of malaria, but also of other diseases transmitted by the same type of vector.

Malaria, Anopheles, Ivermectin, Artemether-lumefantrine, Cost-effectiveness --- Sciences de la santé humaine > Santé publique, services médicaux & soins de santé

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The importance of natural products, and especially plant secondary metabolites, for the treatment of diseases and drug development has already been obvious in medicine for several thousand years. Thus, this Special Issue of MDPI Biomedicines collects eight top articles from the field as regular full papers in addition to five reviews. All of the published papers are a vibrant source of information on the therapeutic potential of plant secondary metabolites in the treatment of diseases and drug development.

Cannabis sativa (Cannabis) --- cannabinoids --- tetrahydrocannabinol (THC) --- cannabidiol (CBD) --- cannabinoid receptors (CB1 and CB2) --- Papaver somniferum (opium poppy) --- secondary metabolites --- ursolic acid --- NSCLC --- tumorsphere --- EGFR --- STAT3 --- MMP2 --- PD-L1 --- MAFLD --- tanshinone IIA --- phytochemical --- lipogenesis --- lipid accumulation --- LXRα --- malaria --- quinine --- chloroquine --- artemisinin --- onchocerciasis --- ivermectin --- moxidectin --- cancer --- vincristine --- vinblastine --- anabolic --- diabetes --- Duchenne muscular dystrophy --- β-ecdysone --- ecdysteroid --- ecdysterone --- Mas1 --- osteoporosis --- sarcopenia --- COVID-19 --- cardiometabolic diseases --- respiratory diseases --- natural product --- SARS-CoV-2 --- lung cancer --- United States Food and Drug Administration-approved drug --- natural remedy --- triterpenoid --- molecular ribbon --- Huisgen 1,3-dipolar cycloaddition --- amide bond --- multifunctional PEG3 derivative --- antimicrobial activity --- anti-HIV activity --- cytotoxicity --- supramolecular self-assembly --- phytocannabinoids --- cannabichromene --- thermos-TRPs --- TRPA1 --- α,α-dimethylheptyl effect --- betulinic acid --- BODIPY --- bevirimat --- cell-cycle --- fluorescent microscopy --- maturation inhibitor --- capsaicinoids --- endocannabinoidome --- microbiota --- overweight --- obesity --- food intake --- lipidomics --- metabolism --- alkaloids --- membrane fusion --- viral fusion inhibitor --- antiviral therapy --- curcumin --- cancer cells --- bioavailability --- curcumin derivatives --- curcumin analogues --- curcumin delivery systems --- natural product synthesis --- lignans --- inflammation --- NF-κB inhibition --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The importance of natural products, and especially plant secondary metabolites, for the treatment of diseases and drug development has already been obvious in medicine for several thousand years. Thus, this Special Issue of MDPI Biomedicines collects eight top articles from the field as regular full papers in addition to five reviews. All of the published papers are a vibrant source of information on the therapeutic potential of plant secondary metabolites in the treatment of diseases and drug development.

Technology: general issues --- Chemical engineering --- Cannabis sativa (Cannabis) --- cannabinoids --- tetrahydrocannabinol (THC) --- cannabidiol (CBD) --- cannabinoid receptors (CB1 and CB2) --- Papaver somniferum (opium poppy) --- secondary metabolites --- ursolic acid --- NSCLC --- tumorsphere --- EGFR --- STAT3 --- MMP2 --- PD-L1 --- MAFLD --- tanshinone IIA --- phytochemical --- lipogenesis --- lipid accumulation --- LXRα --- malaria --- quinine --- chloroquine --- artemisinin --- onchocerciasis --- ivermectin --- moxidectin --- cancer --- vincristine --- vinblastine --- anabolic --- diabetes --- Duchenne muscular dystrophy --- β-ecdysone --- ecdysteroid --- ecdysterone --- Mas1 --- osteoporosis --- sarcopenia --- COVID-19 --- cardiometabolic diseases --- respiratory diseases --- natural product --- SARS-CoV-2 --- lung cancer --- United States Food and Drug Administration-approved drug --- natural remedy --- triterpenoid --- molecular ribbon --- Huisgen 1,3-dipolar cycloaddition --- amide bond --- multifunctional PEG3 derivative --- antimicrobial activity --- anti-HIV activity --- cytotoxicity --- supramolecular self-assembly --- phytocannabinoids --- cannabichromene --- thermos-TRPs --- TRPA1 --- α,α-dimethylheptyl effect --- betulinic acid --- BODIPY --- bevirimat --- cell-cycle --- fluorescent microscopy --- maturation inhibitor --- capsaicinoids --- endocannabinoidome --- microbiota --- overweight --- obesity --- food intake --- lipidomics --- metabolism --- alkaloids --- membrane fusion --- viral fusion inhibitor --- antiviral therapy --- curcumin --- cancer cells --- bioavailability --- curcumin derivatives --- curcumin analogues --- curcumin delivery systems --- natural product synthesis --- lignans --- inflammation --- NF-κB inhibition --- n/a